Methylprednisolone pulse therapy: An alternative management of severe COVID-19

Bryce-Alberti, M.; Sauñe, P.M.; Accinelli Tanaka, Roberto Alfonso; Portmann Baracco, Arianna Sibila

dc.contributor.author	Sauñe, P.M.
dc.contributor.author	Bryce-Alberti, M.
dc.contributor.author	Portmann Baracco, Arianna Sibila
dc.contributor.author	Accinelli Tanaka, Roberto Alfonso
dc.date.accessioned	2020-12-14T16:10:11Z
dc.date.available	2020-12-14T16:10:11Z
dc.date.issued	2020
dc.identifier.uri	https://hdl.handle.net/20.500.12866/8799
dc.description.abstract	We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asymptomatic disease, non-severe symptomatic disease, and severe respiratory inflammatory disease. The first two forms are dependent on viral response and a “cytokine storm” is responsible for the progression into severe disease. Glucocorticoids (GC) reduce inflammation by different mechanism depending of their concentration. Pulses lead to overall apoptosis of immune cells. Studies using pulse MP as treatment for SARS-CoV-1 showed clinical improvement and decreased incidence of ARDS compared with patients who received low dose steroid treatment. Inhibition of excessive inflammation through timely administration of GC in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS.	en_US
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Respiratory Medicine Case Reports
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	COVID-19	en_US
dc.subject	Cytokine storm	en_US
dc.subject	Treatment	en_US
dc.subject	Pulse therapy	en_US
dc.subject	Methylprednisolone	en_US
dc.title	Methylprednisolone pulse therapy: An alternative management of severe COVID-19	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1016/j.rmcr.2020.101221
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.07
dc.relation.issn	2213-0071